Usually reported as HER2-negative and classified as TNBC or luminal-like in clinical practice, HER2-low BC is a heterogeneous disease and shows distinct molecular profile and prognosis compared with tumors negative for HER2 by IHC [35]. The gene discussed is ERBB2; the disease is breast cancer.